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In our 2016 paper in Nature, we demonstrated that 
the transcription factors (TFs) p53 and c-MYC comprise 
a dual signaling “hub” in Chronic Myeloid Leukaemia 
(CML) leukaemic stem cells  (LSC)[1]. This finding 
was derived from differential expression and network 
analyses of several proteomic and transcriptomic datasets 
describing CML LSC and normal stem/progenitor cells 
(SPC).  Perturbation of this dual hub using gene knock-
down strategies and/or specific drugs targeting the hub 
was shown to induce selective kill of LSC (the primitive 
stem cells that are responsible for initiating and sustaining 
the disease [2]). Importantly no such effects were observed 
on normal SPC, across a range of experimental in vitro 
models, and two in vivo murine models of CML.
It was essential to validate the in silico CML 
network analysis that identified the two TFs as therapeutic 
targets.  Specifically, we sought to address the concern 
that, as p53 and c-MYC are a tumour suppressor and 
oncogene, respectively, we would expect to find them 
as hubs in network analyses of any oncogenic data. 
Furthermore, our observation could theoretically be 
compounded by literature bias, given that p53 and c-MYC 
are extensively studied in biological research and therefore 
over-represented in resources used to build interaction 
networks.  Here, we seek to describe our approach to these 
concerns in more detail.
Our candidate network of 58 proteins emerged from 
(1) an analysis of isobaric-tag mass spectrometry (MS) 
data measuring relative protein expression in SPC from 
CML patients (n=3) and healthy donors (n=2), and (2) a 
subsequent network analysis (using MetaCore) to identify 
important regulators of the CML LSC specific proteomic 
signature.  As mentioned above, p53 and c-MYC emerged 
as the two primary hubs (see Figure 1(a) in [1]).
To ensure that this process was not susceptible 
to literature bias, we subjected 50 random sets of 
proteins (drawn from the >4000 proteins observed in 
the MS experiments) to the same network analysis. The 
connectivity of p53 and c-MYC within these random 
networks was then determined. Critical to our hypothesis, 
viable pharmacological target nodes need to be (i) densely 
connected to and (ii) lie upstream of signaling pathways. 
In order to compare our observations in the CML network 
with other networks, we calculated a topological bias 
statistic (dout/din), to quantify the ratio of outgoing to 
incoming connections for each protein. This value will 
increase as the number of outgoing connections exceeds 
the number of incoming connections; therefore high ratios 
indicate predominantly upstream connectivity.  With an 
understanding of how this ratio varies for both p53 and 
c-MYC in randomly generated data sets of proteins, we 
were able to assess whether the topological ratios for 
p53 and c-MYC observed in our CML network were 
likely to have occurred by chance.  Figure 1 shows that 
our CML network (red) fell outwith the random network 
distributions (summarised by grey contours), with only 
2/50 random networks demonstrating equivalent or greater 
upstream bias (p=0.04) for p53 and c-MYC.  Interestingly, 
the topological analyses of two proteomic datasets derived 
from Ba/F3 cell lines expressing leukaemogenic protein 
tyrosine kinases (TK; e.g., Flt3-ITD, Fip1L/PDGFRα) fell 
largely within the region occupied by the random protein 
sets, including the Ba/F3 cell line transduced with the 
BCR-ABL1 oncogene [3].  We interpreted this to suggest, 
firstly, that malignancies driven by constitutively active 
protein TK may not share aberrant signaling networks 
(at least not those that depend on p53 and/or c-MYC) 
and, secondly, that cell line models are limited in their 
replication of the signaling pathways found in primary 
material, such as CML LSC.  Ultimately, these results 
demonstrate that there was no evidence of a confounding 
literature bias in our methodology.
To assess the second point (whether our dual 
hub was observable in other malignant diseases), we 
repeated the analysis in other datasets comparing primary, 
human cancer cells to their closest normal counterparts. 
Optimising MS technologies to assay these cells is 
technically challenging and as such, very few datasets 
exist that compare to our study and to which we could 
apply our methods.  We were able to identify two such 
datasets, capturing proteomic expression in two clinical 
subtypes of breast cancer [4] and three clinical subtypes 
of prostate cancer [5].  The topological ratios for p53 
and c-MYC in the context of breast (light blue) and 
prostate (dark blue) cancer are shown alongside those 
of the CML network, the random protein sets and the 
previously analysed cell line datasets (Figure 1). Unlike 
the cell line data, these primary cell results fall largely 
outwith the random distributions, reinforcing the idea that 
cell lines are limited in their ability to replicate signaling 
pathways found in primary cells.  It is also clear that the 
prostate cancer network showed only a dominant p53 bias 
(with MTA and CREB1 emerging as more dominantly 
upstream), whilst the breast cancer network demonstrated 
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a dual, but weaker p53/c-MYC signature, as compared to 
CML (here, a stronger upstream bias was observed for 
CREB1, TIF1-beta and coagulation factor XIIIA).
This  work corroborates our original finding that p53 
and c-MYC have dominant roles in CML signaling, which 
was substantiated in the subsequent laboratory validation 
[1]. This work represents a novel paradigm in which an 
unbiased systems biology approach performed on primary 
patient SPC has uncovered a novel therapeutic drug 
combination.  This work also represents an innovative 
clinical intervention for CML and as a result, we are 
actively progressing a drug combination targeting the hub 
towards clinical trial.
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Figure 1: Validating a dual hub network topology. Plotting the ratio of outgoing (dout) to incoming (din) connections to understand 
the role of p53 and c-MYC in each network.  Other primary datasets shown in blue, cell line datasets shown in green, random networks 
summarised by grey contours and our CML network shown in red.
